Business News›Roche Holding AG
SEARCHED FOR:
ROCHE HOLDING AG
Near-4,000% surge catapults one tiny biotech firm to record week
Shares of Tempest have come off that high in the two latest trading sessions as investor enthusiasm moderated and a broader market selloff in risky assets batters the high-risk biotechnology sector. The firm’s market value of $49 million on Friday remains more than 15-fold of what it was, before the jump.
Market stampede turns favorite defensive trades into danger zone
Investors may not be fully protected by the rush for defensive assets, experts have warned. The consequent surge in prices for tech stocks and high-grade corporate bonds could leave them exposed to a potentially painful reversal, according to Frederique Carrier, head of investment strategy at RBC Wealth Management. Investment analysts are advising a different approach that includes low-volatility shares and short credit positions. A Bank of America fund manager survey reflected investor confidence that tech firms with strong balance sheets would weather a recession, the survey also revealed record bullish positioning in investment-grade credit over high yield.
At last, a drug to slow down Alzheimer's
Eisai Co, a Tokyo-based pharmaceutical company with a family bent and market capitalisation of $14 billion, crossed the finish line before behemoths valued nearly 20-fold higher, including industry leaders Roche Holding AG and Eli Lilly & Co
SoftBank liquidates most of portfolio at ‘Nasdaq whale’ unit
Akshay Naheta, a senior SoftBank executive who had worked on some of the company’s biggest deals, also left the company on Thursday
These are the stocks to watch as Covid enters its next phase
The first pill to treat Covid-19 is on its way and vaccine producers are rolling out booster shots in wealthy countries. For investors, the next stage of the pandemic means a tougher landscape for stockpicking. Nineteen months into the pandemic, a successful rollout of a Covid-19 pill could quicken and broaden the world’s recovery, opening up a plethora of investment opportunities in stock markets.
Ahead of crucial AGM, Toshiba board chairman vows to be 'agent of positive change'
Nagayama has come under intense pressure to resign after an explosive independent investigation this month found that Toshiba colluded with the Japanese government to block foreign shareholders from having influence on the board.
- Go To Page 1
New antibody tests offer better snapshot of Covid-19 immunity
Antibodies are markers of infection, and testing for them helps health officials see how widely the virus has spread. Until now, most tests could tell only whether they’re present. The newer ones go a step further, measuring the quantity of these proteins, which are raised by the immune system to disable viral invaders.
What are T cells, the unsung immune players that take over when Covid antibodies wane?
T cells are able to kill virus-infected cells, remember past diseases for decades, and rouse fresh antibody soldiers long after the first have left the battlefield.
Britain agrees to acquire antibody tests, boosting Coronavirus response
Widespread availability of antibody tests may help Britain lift its lockdown restrictions, because they show who has already had the virus and might have a degree of immunity, meaning they can resume social contact with others.
Scientists create antibody that claims to defeat coronavirus in lab
More research is needed to see whether the findings are confirmed in a clinical setting and how precisely the antibody defeats the virus.
Roche gets US nod for Covid-19 antibody test
Hospitals and reference laboratories can run the Elecsys Anti-SARS-CoV-2 test on one of Roche’s analysis platforms, the company said. Roche’s antibody test has a specificity of more than 99.8% and 100% sensitivity, meaning that it not only reliably identifies patients who've developed antibodies but also can filter out those who haven’t, reducing misdiagnoses.
European shares gain on hopes of easing in lockdown measures
The pan-European STOXX 600 index was up 1.1 per cent, after tumbling more than 3 per cent on Tuesday following a historic collapse in oil prices.
Unilever, 3M on list of firms eligible for China loans to ease coronavirus crisis
Some lenders in the city have each received a list of firms compiled by the Shanghai branches of the Ministry of Industry and Information Technology (MIIT) and the National Development and Reform Commission (NDRC). Companies have the option to nominate themselves to be added to the overall list. Each lender then determines independently whether to approach a company on its list and offer finance, according to the bankers. Companies producing medical supplies and which are "backbone enterprises" providing daily necessities are eligible for the special loans, according to a notice on the Shanghai MIIT's website.
True North buys into Biocon Biologics, deal values firm at around $3.5 billion
True North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valuing the unlisted arm at $3-3.5 billion (Rs 25,000 crore), said two people aware of the development. This is the first step of a larger $200-300 million fundraising round that’s expected to close before mid-2020.
This drug may replace chemotherapy, redefine cancer care
These drugs will attack cancer cells in the body without damaging surrounding healthy ones.
Novartis CEO Jimenez to quit giving reins to Vasant Narasimhan
Jimenez is handing over the reins at a crucial juncture, with the drugmaker yet to make a decision on the future of its ailing Alcon eye-care business.
‘Day From Hell’ looms as companies worth $3 trillion to post earnings on Thursday
With so many cos reporting, analysts will try to spot results that differ from expectations.
Where to hide if Trump's policies go bad? Top investors say go for gold
The amount of political risk being created by Trump and his administration is going to create an enormous amount of international tension and uncertainty.
Court defers decision on Roche's plea against Zydus' cancer drug
Roche sued Zydus Cadila and the DCGI last week, alleging that the Indian company launched its product, Vivitra, in the country without generating its own clinical trial data.
Dr Reddy's, Endo get FDA approval to launch generic Valcyte
The move comes after Ranbaxy said that FDA had stripped the company of its tentative approval to launch the first copy of the drug.
Dr Reddy's Laboratories rallies over 6%, hits 52-week high on USFDA approval
Ranbaxy recouped its intraday losses and was trading 1.2 per cent higher at Rs 661.20. It hit a low of Rs 623 and a high of Rs 664.25 in trade today.
Ranbaxy slips nearly 5% as US pulls approval for AstraZeneca and Roche drugs
The FDA has stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow.
Swiss voters reject strictest executive pay limits
Swiss voters rejected a proposal to limit executives’ pay to 12 times that of junior employees on Sunday.
Merck unit sues Glenmark Pharmaceuticals for infringing patent on diabetes drugs
A unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
Pfizer to appeal India decision to revoke cancer drug patent
Pfizer Ltd, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug Sutent.Roche Holding AG makes $5.7 bn offer for Illumina Inc
A takeover of Illumina would be Roche’s largest purchase since the $46.8 billion acquisition of Genentech Inc., completed in March 2009.Roche says half-year profit down 29 per cent
Pharmaceuticals maker Roche Holding AG says net income was down 29 per cent for the first half after the takeover of Genentech.Roche seals $47-b Genentech deal
Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44% of biotech pioneer Genentech that it doesn’t already own, ending a long corporate struggle with its US-based cancer drug partner.Roche makes 'cheaper' bid for Genentech
Roche Holding AG lowered the acquisition price by 2.8% and took the offer for the US cancer-drug developer directly to shareholders.Load More
BACK TO TOP